New study shows that quercetin may be effective adjuvant therapy of mild to moderate COVID-19
Research on Indena’s (Milan, Italy) proprietary Quercetin Phytosome continues to demonstrate potential benefits for managing COVID-19 symptoms and illness. In a recently published open-label randomized controlled clinical trial,1 100 patients with mild to moderate COVID-19 were given either standard care in addition to 500 mg of Quercetin Phytosome per day or standard care with placebo for two weeks. Results showed that patients in the Quercetic group experienced a speedy recovery after one week of treatment, with 34 patients testing negative of for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to 12 patients in the placebo group. Patients in the quercetic group also experienced resolution of their COVID-19-associate acute symptoms, compared to 12 patients in the placebo group.

“Moreover, participants in the quercetin group also showed statistically significant improvement in the serum levels of inflammatory biomarker LDH,” explained Antonella Riva, head of product innovation and development for Indena S.p.A, in a press release. “Also, the outcomes of our last study then suggest possible quercetin supplementation effectiveness in the early-stage mild to moderately symptomatic COVID-19 outpatients and may help in optimizing the clearance of the SARS-CoV- 2 infection, mildening of the symptoms and modulation/control of the host’s inflammatory response. The study also supports the safety of quercetin supplementation in subjects with COVID-19 which has an unpredictable and complex course and hence may be potentially used as an adjuvant alongside routine care in the management of mild to moderate symptoms of COVID-19.”

This latest study builds on previous research demonstrating the ingredients potential benefits in managing COVID-19 illness. “We keep devoting resources to clinical research with the aim to get stronger and stronger scientific evidences about Indena’s ingredients. We’re very happy and proud to see such results from our Quercefit® and to give our contribution in helping people’s health which has had to face one of the most serious pandemics in recent years” added Stefano Togni, chief commercial officer of Indena S.p.A.


Di Pierro, F; Khan, A.; Iqtadar, S.; Mumtaz, S.U.; et al. Quercetin as a Possible Complementary Agent for Early-Stage COVID-19: Concluding Results of a Randomized Clinical Trial. Front. Pharmocol. 13, 2022: DOI: 10.3389/fphar.2022.1096853
Papers in This Article